Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal Sampling Site for the Diagnosis of <i>Helicobacter pylori</i> Infection with the Rapid Urease Test: A Prospective Cohort Study.

Gut and liver·2026
Same author

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy.

Journal of gastric cancer·2026
Same author

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors.

Future oncology (London, England)·2026
Same author

Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors.

Cancer research·2026

Related Experiment Video

Updated: Apr 8, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.7K

Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification.

In Hye Song1, Soomin Ahn2, Hyung-Don Kim3

  • 1Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Journal of Gastric Cancer
|April 6, 2026
PubMed
Summary
This summary is machine-generated.

Gastrointestinal stromal tumors (GIST) have evolved from KIT/PDGFRA mutations to include alternative targets. Current risk classification systems for GIST face challenges due to inconsistent mitotic counting and reporting.

Keywords:
Gastrointestinal stromal tumorsHistoryMutationPrognosisRisk assessment

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

18
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
05:16

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

6.7K

Related Experiment Videos

Last Updated: Apr 8, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.7K
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

18
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
05:16

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

6.7K

Area of Science:

  • Gastrointestinal Pathology
  • Molecular Oncology
  • Surgical Oncology

Background:

  • Gastrointestinal stromal tumors (GIST) are common mesenchymal neoplasms.
  • KIT/PDGFRA mutations historically defined GIST, leading to imatinib therapy.
  • Alternative mutations (SDH, BRAF) necessitate diverse targeted therapies.

Purpose of the Study:

  • To review the historical context, molecular subtypes, and risk classification of GIST.
  • To highlight evolving challenges in mitotic rate evaluation for GIST risk stratification.
  • To discuss the clinical application of GIST risk classification systems.

Main Methods:

  • Comprehensive literature review of GIST.
  • Analysis of molecular diagnostics and targeted therapy development.
  • Examination of risk classification systems and mitotic counting methodologies.

Main Results:

  • GIST classification has expanded beyond KIT/PDGFRA mutations.
  • Multiple, inconsistent risk classification systems are currently in use.
  • Mitotic counting presents challenges due to digital pathology and guideline discrepancies.

Conclusions:

  • Advances in molecular diagnostics have broadened therapeutic options for GIST.
  • Inconsistencies in risk stratification hinder accurate pathologic reporting and clinical communication.
  • Standardizing mitotic counting and risk assessment is crucial for improved GIST management.